Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

PURPOSE Mutations within the KRAS proto-oncogene have predictive value but are of uncertain prognostic value in the treatment of advanced colorectal cancer. We took advantage of PETACC-3, an adjuvant trial with 3,278 patients with stage II to III colon cancer, to evaluate the prognostic value of KRAS and BRAF tumor mutation status in this setting. PATIENTS AND METHODS Formalin-fixed paraffin-embedded tissue blocks (n = 1,564) were prospectively collected and DNA was extracted from tissue sections from 1,404 cases. Planned analysis of KRAS exon 2 and BRAF exon 15 mutations was performed by allele-specific real-time polymerase chain reaction. Survival analyses were based on univariate and multivariate proportional hazard regression models. RESULTS KRAS and BRAF tumor mutation rates were 37.0% and 7.9%, respectively, and were not significantly different according to tumor stage. In a multivariate analysis containing stage, tumor site, nodal status, sex, age, grade, and microsatellite instability (MSI) status, KRAS mutation was associated with grade (P = .0016), while BRAF mutation was significantly associated with female sex (P = .017), and highly significantly associated with right-sided tumors, older age, high grade, and MSI-high tumors (all P < 10(-4)). In univariate and multivariate analysis, KRAS mutations did not have a major prognostic value regarding relapse-free survival (RFS) or overall survival (OS). BRAF mutation was not prognostic for RFS, but was for OS, particularly in patients with MSI-low (MSI-L) and stable (MSI-S) tumors (hazard ratio, 2.2; 95% CI, 1.4 to 3.4; P = .0003). CONCLUSION In stage II-III colon cancer, the KRAS mutation status does not have major prognostic value. BRAF is prognostic for OS in MS-L/S tumors.

[1]  G. Gaudernack,et al.  K-ras mutations and prognosis in large-bowel carcinomas. , 1997, Scandinavian journal of gastroenterology.

[2]  A. Norman,et al.  Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. , 1998, Journal of the National Cancer Institute.

[3]  J. Benhattar,et al.  The type of K-ras mutation determines prognosis in colorectal cancer. , 1998, American journal of surgery.

[4]  F. Bosman,et al.  p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. , 2000, European journal of cancer.

[5]  Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study , 2001, British Journal of Cancer.

[6]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[7]  K. Kinzler,et al.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.

[8]  T. Kawabe,et al.  Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. , 2003, Cancer research.

[9]  A. Goel,et al.  Ki-ras gene mutations, LOH of the APC and DCC genes, and microsatellite instability in primary colorectal carcinoma are not associated with micrometastases in pericolonic lymph nodes or with patients’ survival , 2004, Journal of Clinical Pathology.

[10]  K. Fransén,et al.  Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. , 2003, Carcinogenesis.

[11]  A. Fernández-Peralta,et al.  Simultaneous Mutations in K-ras and TP53 Are Indicative of Poor Prognosis in Sporadic Colorectal Cancer , 2004, American journal of clinical oncology.

[12]  W. Grady.  Genomic instability and colon cancer , 2004, Cancer and Metastasis Reviews.

[13]  G Smith,et al.  The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma , 2005, Gut.

[14]  H. Hollema,et al.  Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A E Ades,et al.  The Interpretation of Random-Effects Meta-Analysis in Decision Models , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.

[16]  S. Corsale,et al.  Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  R. Wolff,et al.  Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. , 2005, Cancer research.

[18]  A. Russo,et al.  Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Suzanne Schubbert,et al.  Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.

[20]  B. Leggett,et al.  Colorectal carcinogenesis: road maps to cancer. , 2007, World journal of gastroenterology.

[21]  Silvia Benvenuti,et al.  Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. , 2007, Cancer research.

[22]  Emily J. Greenspan,et al.  Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. , 2007, Cancer Research.

[23]  J. Baselga,et al.  Determinants of RASistance to anti-epidermal growth factor receptor agents. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Houlston,et al.  Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis , 2008, Gut.

[25]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Shuji Ogino,et al.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer , 2008, Gut.

[27]  Pierre Laurent-Puig,et al.  Mutations in the RAS‐MAPK, PI(3)K (phosphatidylinositol‐3‐OH kinase) signaling network correlate with poor survival in a population‐based series of colon cancers , 2008, International journal of cancer.

[28]  D. Cunningham,et al.  Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Martin J Tobin,et al.  Meta-analysis under the spotlight: Focused on a meta-analysis of ventilator weaning* , 2008, Critical care medicine.

[30]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Seruca,et al.  BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAFV600E but not KRAS mutations , 2008, The Journal of pathology.

[32]  M. Kloor,et al.  Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. , 2008, Gastroenterology.

[33]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[35]  R. Greil,et al.  Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.